Viking Therapeutics Stock News

Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.

Fennec (FENC) suffers a setback again with a CRL for its new drug application (NDA) for Pedmark. Shares are down in pre-market trading.

Bristol Myers' (BMY) performance has been good of late, driven by Revlimid, Eliquis, Opdivo and its new product portfolio amid stiff competition.

Bristol Myers (BMY) wins EC approval for Zeposia for a second indication ??? ulcerative colitis.

Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC.

Bristol Myers (BMY) announces extension of FDA review of its cardiovascular drug mavacamten. The new target action date is Apr 28, 2022.

Equities research analysts forecast that Viking Therapeutics, Inc. (NASDAQ:VKTX) will post ($0.19) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Viking Therapeutics earnings. The highest EPS estimate is ($0.17) and the lowest is ($0.22). Viking Therapeutics reported earnings of ($0.15) per share in the []

The average of price targets set by Wall Street analysts indicates a potential upside of 225.8% in Viking Therapeutics, Inc. (VKTX). While the effectiveness of this highly sought-after metric is quest

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Viking Therapeutics, Inc. (VKTX) CEO Brian Lian on Q3 2021 Results - Earnings Call Transcript

The consensus price target hints at a 204.1% upside potential for Viking Therapeutics, Inc. (VKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in

SAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and

SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and

SAN DIEGO, Sept. 2, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an